Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
N/A N=51 Health-Kit Enabled Mobile App for Tobacco Cessation
Cigarette Smoking
Primary: Psychosocial Expectancies (PROMIS Smoking Initiative) Patient Reported Outcome — 12.7; 13.6 score on a scale — p=0.17
N/A N=1,094 Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Smoking Cessation
Primary: Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey — 13.0; 13.5 percentage of participants — p=0.865
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Phase 4 N=1,346 Smoking Cessation Intervention: Effectiveness in Primary Care
Tobacco Dependence
Primary: 6 Month Self-reported Abstinence From Smoking — 50; 52; 45; 75 participants
Phase 4 N=1,504 Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
Nicotine Dependence
Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO
Phase 4 N=52 Tobacco Treatment Comparison for Cancer Care
Smoking Cessation · Cancer
Primary: Biochemically Verified 7-day Point-prevalence Abstinence 26 Weeks After a Target Quit Date. — 2; 7 Participants
N/A N=56 Engaging Patients in Tobacco Cessation Resources in Dental Settings
Smoking
Primary: Percentage of Smokers With Delivery of Brief Interventions and/or Referral to Treatment — 7; 36 Participants
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
Phase 1 N=58 Persistence-Targeted Smoking Cessation
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants
Phase 4 N=1,270 Smoking Cessation in Hospitalized Smokers
Smoking Cessation
Primary: Percentage of Participants With 30-day Abstinence — 18.0; 23.4; 22.1; 18.7 percentage of participants
Phase 4 N=987 Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines
Smoking · Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking by Intervention — 43.3; 48.9; 42.3; 49.9 Percentage of participants not smoking — p=.076
N/A N=303 Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Smoking Cessation
Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
Phase 4 N=432 Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
Tobacco Use Cessation
Primary: Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco — 125; 85 participants — p=<0.0001
Phase 2 N=49 Smoking Cessation Intervention for Thoracic Patients
Lung Cancer
Primary: Determination of the Feasibility of a Cognitive Behavioral Smoking Cessation Intervention. — 17; 32 participants
N/A N=154 Enhancing a High School Based Smoking Cessation Program
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
Phase 2 N=118 St. John's Wort for Tobacco Cessation
Smoking · Nicotine Dependence
Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 7; 8; 6 participants — p=0.52
Phase 4 N=544 Evaluation of Treatments to Improve Smoking Cessation Medication Adherence
Smoking · Smoking Cessation · Adherence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 197; 181; 202; 176 participants — p=.011
Phase 2 N=237 Efficacy of Varenicline for Smokeless Tobacco Use in India
Tobacco Use Disorder
Primary: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. — 30; 23 participants
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
N/A N=78 Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women
Smoking Cessation
Primary: Change in the Number of Cigarettes Smoked Per Day — 0; 0 cigarettes per day
N/A N=120 Telephone Counseling for Tobacco Cessation
Tobacco Use Cessation
Primary: The Percentage of Self-reported Tobacco Cessation Attempts Between Groups — 8; 5 participants
N/A N=51 Smoking Cessation E-Visit
Smoking
Primary: Number of Participants Who Utilized Smoking Cessation Treatment — 15; 3 Participants
N/A N=6,009 Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)
Smoking
Primary: Count of Participants Not Smoking — 766 Participants
Phase 3 N=143 Extended Cessation Treatment for Teen Smokers
Nicotine Dependence
Primary: Point Prevalence Abstinence — 15; 5 participants
N/A N=190 Reducing Tobacco Use Disparities Among Low-Income Adults
Cigarette Smoking · Nicotine Dependence
Primary: Quitline Treatment Engagement — 25; 0 Participants
Phase 2 N=184 Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
Cigarette Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants